Pacira Pharmaceuticals(PCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PCRX Pacira Pharmaceuticals

休市中 02-06 16:00:00 EST

21.00

+0.64

+3.14%

盘后21.00

+0.000.00%

18:40 EST

最高21.07	最低20.44	成交量74.65万
今开20.61	昨收20.36	日振幅3.12%
总市值9.03亿	流通市值7.95亿	总股本4,302万
成交额1,557万	换手率1.97%	流通股本3,784万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PCRX","market":"US","secType":"STK","nameCN":"Pacira Pharmaceuticals","latestPrice":21,"timestamp":1770411600000,"preClose":20.36,"halted":0,"volume":746544,"hourTrading":{"tag":"盘后","latestPrice":21,"preClose":21,"latestTime":"18:40 EST","volume":238082,"amount":4999719.67,"timestamp":1770421256134,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.031434184675834996,"floatShares":37844000,"shares":43021275,"eps":0.471309,"marketStatus":"休市中","change":0.64,"latestTime":"02-06 16:00:00 EST","open":20.61,"high":21.07,"low":20.435,"amount":15569104.944864,"amplitude":0.031189,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.471309,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1296709200000,"exchange":"NASDAQ","adjPreClose":20.36,"preHourTrading":{"tag":"盘前","latestPrice":20.84,"preClose":20.36,"latestTime":"08:55 EST","volume":1,"amount":20.84,"timestamp":1770386158983,"change":0.48,"changeRate":0.023576,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":21,"preClose":21,"latestTime":"18:40 EST","volume":238082,"amount":4999719.67,"timestamp":1770421256134,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0690569678511987,"impliedVol":0.4175,"impliedVolPercentile":0.1873},"requestUrl":"/m/hq/s/PCRX","defaultTab":"news","newsList":[{"id":"1115416803","title":"Doma Perpetual资本管理公司：主张Pacira Pharmaceuticals董事会应立即寻求出售公司","url":"https://stock-news.laohu8.com/highlight/detail?id=1115416803","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115416803?lang=zh_cn&edition=full","pubTime":"2025-12-30 23:44","pubTimestamp":1767109472,"startTime":"0","endTime":"0","summary":"Doma Perpetual资本管理公司发布声明，强烈建议Pacira Pharmaceuticals董事会立即启动公司出售程序。该投资机构认为，此举符合股东利益最大化原则，并有望为公司带来显著的估值提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"1138159752","title":"Pacira Biosciences公布12个月试点研究结果：Iovera°在慢性下背痛治疗中相比于射频消融显示出良好的安全性及显著的疼痛改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1138159752","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138159752?lang=zh_cn&edition=full","pubTime":"2025-12-02 21:13","pubTimestamp":1764681190,"startTime":"0","endTime":"0","summary":"Pacira Biosciences公布了为期12个月的试点研究结果，该研究显示Iovera°在慢性下背痛的治疗中相比于射频消融具有良好的安全性及显著的疼痛改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"1107913418","title":"Pacira Biosciences：因诉讼触发Hatch-Waxman法案下Andas最终FDA批准的30个月暂停","url":"https://stock-news.laohu8.com/highlight/detail?id=1107913418","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107913418?lang=zh_cn&edition=full","pubTime":"2025-11-27 05:04","pubTimestamp":1764191067,"startTime":"0","endTime":"0","summary":"Pacira Biosciences：因诉讼触发Hatch-Waxman法案下Andas最终FDA批准的30个月暂停","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"1192407488","title":"Pacira Biosciences: 寻求禁令以阻止生产、使用及销售在每家公司的ANDA中描述的仿制产品","url":"https://stock-news.laohu8.com/highlight/detail?id=1192407488","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192407488?lang=zh_cn&edition=full","pubTime":"2025-11-27 05:03","pubTimestamp":1764190989,"startTime":"0","endTime":"0","summary":"Pacira Biosciences: 寻求禁令以阻止生产、使用及销售在每家公司的ANDA中描述的仿制产品","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"1183145210","title":"Pacira Pharmaceuticals对Whiteoak集团和齐鲁制药提起Exparel®专利侵权诉讼","url":"https://stock-news.laohu8.com/highlight/detail?id=1183145210","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183145210?lang=zh_cn&edition=full","pubTime":"2025-11-27 05:02","pubTimestamp":1764190931,"startTime":"0","endTime":"0","summary":"Pacira Pharmaceuticals对Whiteoak集团和齐鲁制药提起Exparel®专利侵权诉讼。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"2585128370","title":"Pacira Biosciences, Inc.盘中异动 股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585128370","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585128370?lang=zh_cn&edition=full","pubTime":"2025-11-21 04:38","pubTimestamp":1763671120,"startTime":"0","endTime":"0","summary":"北京时间2025年11月21日04时38分，Pacira Biosciences, Inc.股票出现异动，股价快速下挫5.08%。Pacira Biosciences, Inc.股票所在的制药行业中，整体跌幅为0.79%。其相关个股中，Scynexis, Inc.、Therapeuticsmd, Inc.、Scilex Holding Company涨幅较大，Inmed Pharmaceuticals Inc.、Akanda Corp.、Hims & Hers Health, Inc.较为活跃，换手率分别为260.86%、10.26%、10.23%，振幅较大的相关个股有Scilex Holding Company C/Wts 10/11/2027 、Therapeuticsmd, Inc.、Scilex Holding Company，振幅分别为30.94%、29.78%、22.41%。Pacira Biosciences, Inc.公司简介：Pacira BioSciences Inc 是一家非阿片类疼痛管理和再生健康解决方案的提供商，致力于推进和改善医疗从业者及其患者的结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112104384097762d18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112104384097762d18&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"1114445344","title":"Doma Perpetual致信敦促Pacira Pharmaceuticals董事会立即探讨出售业务的可能性","url":"https://stock-news.laohu8.com/highlight/detail?id=1114445344","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114445344?lang=zh_cn&edition=full","pubTime":"2025-11-11 09:12","pubTimestamp":1762823547,"startTime":"0","endTime":"0","summary":"Doma Perpetual致信敦促Pacira Pharmaceuticals董事会立即探讨出售业务的可能性","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"1116530155","title":"Pacira Biosciences完成针对膝关节骨关节炎疗法Pcrx-201的二期研究第一部分患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1116530155","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116530155?lang=zh_cn&edition=full","pubTime":"2025-11-05 21:01","pubTimestamp":1762347690,"startTime":"0","endTime":"0","summary":"Pacira Biosciences完成针对膝关节骨关节炎疗法Pcrx-201的二期研究第一部分患者入组。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"1198704824","title":"Amacathera与Pacira Pharmaceuticals达成协议：获得500万美元预付款和最多2.25亿美元的潜在未来里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1198704824","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198704824?lang=zh_cn&edition=full","pubTime":"2025-11-04 20:07","pubTimestamp":1762258047,"startTime":"0","endTime":"0","summary":"Amacathera与Pacira Pharmaceuticals达成协议：获得500万美元预付款和最多2.25亿美元的潜在未来里程碑付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"1199631257","title":"Amacathera与Pacira Pharmaceuticals签署高达2.3亿美元的全球独家许可协议，验证其可调药物递送平台","url":"https://stock-news.laohu8.com/highlight/detail?id=1199631257","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199631257?lang=zh_cn&edition=full","pubTime":"2025-11-04 20:07","pubTimestamp":1762258033,"startTime":"0","endTime":"0","summary":"Amacathera与Pacira Pharmaceuticals签署高达2.3亿美元的全球独家许可协议，验证其可调药物递送平台","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PCRX"],"gpt_icon":0},{"id":"1102021116","title":"Pacira Biosciences与Amacathera签署独家许可协议，推出新型长效镇痛药以控制术后疼痛","url":"https://stock-news.laohu8.com/highlight/detail?id=1102021116","media":"美股速递","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102021116?lang=zh_cn&edition=full","pubTime":"2025-11-04 20:00","pubTimestamp":1762257658,"startTime":"0","endTime":"0","summary":"Pacira Biosciences与Amacathera签署独家许可协议，推出新型长效镇痛药以控制术后疼痛。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"1133811459","title":"Pacira Biosciences：计划主张并执行其知识产权，并在收到PIV通知后有45天的时间提起诉讼","url":"https://stock-news.laohu8.com/highlight/detail?id=1133811459","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133811459?lang=zh_cn&edition=full","pubTime":"2025-10-21 20:33","pubTimestamp":1761049996,"startTime":"0","endTime":"0","summary":"Pacira Biosciences：计划主张并执行其知识产权，并在收到PIV通知后有45天的时间提起诉讼。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"1172557139","title":"Pacira Biosciences 收到来自 Whiteoak Group 针对 Exparel® 的简化新药申请通知","url":"https://stock-news.laohu8.com/highlight/detail?id=1172557139","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172557139?lang=zh_cn&edition=full","pubTime":"2025-10-21 20:32","pubTimestamp":1761049929,"startTime":"0","endTime":"0","summary":"Pacira Biosciences 收到来自 Whiteoak Group 针对 Exparel® 的简化新药申请通知。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2558681748","title":"Pacira Biosciences, Inc.2025财年第二财季实现净利润-4.85百万美元，同比减少125.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558681748","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558681748?lang=zh_cn&edition=full","pubTime":"2025-08-11 00:01","pubTimestamp":1754841693,"startTime":"0","endTime":"0","summary":"8月11日，Pacira Biosciences, Inc.公布财报，公告显示公司2025财年第二财季净利润为-4.85百万美元，同比减少125.67%；其中营业收入为1.81亿美元，同比增加1.69%，每股基本收益为-0.11美元。从资产负债表来看，Pacira Biosciences, Inc.总负债7.79亿美元，其中短期债务2.12亿美元，资产负债比为1.98，流动比率为2.39。机构评级：截至2025年8月11日，当前有5家机构对Pacira Biosciences, Inc.目标价做出预测，其中目标均价为30.80美元，其中最低目标价为24.00美元，最高目标价为44.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000343a4805784&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000343a4805784&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PCRX"],"gpt_icon":0},{"id":"2558579663","title":"Pacira Biosciences, Inc.盘中异动 股价大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558579663","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558579663?lang=zh_cn&edition=full","pubTime":"2025-08-09 01:26","pubTimestamp":1754674015,"startTime":"0","endTime":"0","summary":"北京时间2025年08月09日01时26分，Pacira Biosciences, Inc.股票出现波动，股价快速上涨5.07%。Pacira Biosciences, Inc.股票所在的制药行业中，整体涨幅为0.02%。其相关个股中，Canopy Growth Corporation、Ani Pharmaceuticals, Inc.、Amphastar Pharmaceuticals, Inc.涨幅较大，Incannex Healthcare Inc.、Canopy Growth Corporation、Ani Pharmaceuticals, Inc.较为活跃，换手率分别为164.18%、19.26%、6.33%，振幅较大的相关个股有Canopy Growth Corporation、Alpha Teknova, Inc.、Incannex Healthcare Inc.，振幅分别为31.43%、27.42%、21.49%。Pacira Biosciences, Inc.公司简介：Pacira BioSciences Inc 是一家非阿片类疼痛管理和再生健康解决方案的提供商，致力于推进和改善医疗从业者及其患者的结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809012655a47dab4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809012655a47dab4c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2518447094","title":"Pacira Biosciences, Inc.2024财年实现净利润-99.56百万美元，同比减少337.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518447094","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518447094?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:00","pubTimestamp":1741449618,"startTime":"0","endTime":"0","summary":"3月9日，Pacira Biosciences, Inc.公布财报，公告显示公司2024财年净利润为-99.56百万美元，同比减少337.27%；其中营业收入为7.01亿美元，同比增加3.85%，每股基本收益为-2.15美元。从资产负债表来看，Pacira Biosciences, Inc.总负债7.75亿美元，其中短期债务2.11亿美元，资产负债比为2.01，流动比率为2.41。机构评级：截至2025年3月9日，当前有7家机构对Pacira Biosciences, Inc.目标价做出预测，其中目标均价为30.86美元，其中最低目标价为21.00美元，最高目标价为48.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000024abef96df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000024abef96df&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PCRX"],"gpt_icon":0},{"id":"2516663179","title":"Pacira Biosciences, Inc.盘中异动 股价大跌5.11%报22.82美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516663179","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516663179?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:44","pubTimestamp":1741034657,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时44分，Pacira Biosciences, Inc.股票出现异动，股价急速下挫5.11%。截至发稿，该股报22.82美元/股，成交量68.1483万股，换手率1.47%，振幅5.30%。Pacira Biosciences, Inc.股票所在的制药行业中，整体涨幅为0.77%。Pacira Biosciences, Inc.公司简介：Pacira BioSciences Inc 是一家非阿片类疼痛管理和再生健康解决方案的提供商，致力于推进和改善医疗从业者及其患者的效果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304044417989a6239&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304044417989a6239&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2516583648","title":"巴克莱：维持Pacira BioSciences(PCRX.US)评级，由增持调整至增持评级, 目标价由17.00美元调整至24.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516583648","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516583648?lang=zh_cn&edition=full","pubTime":"2025-03-01 07:12","pubTimestamp":1740784345,"startTime":"0","endTime":"0","summary":"巴克莱：维持Pacira BioSciences(PCRX.US)评级，由增持调整至增持评级, 目标价由17.00美元调整至24.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/01071248470461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PCRX"],"gpt_icon":0},{"id":"2516777379","title":"Pacira Biosciences, Inc.盘中异动 早盘大幅跳水5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516777379","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516777379?lang=zh_cn&edition=full","pubTime":"2025-03-01 00:11","pubTimestamp":1740759087,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日00时11分，Pacira Biosciences, Inc.股票出现异动，股价急速下跌5.02%。Pacira Biosciences, Inc.股票所在的制药行业中，整体跌幅为0.17%。其相关个股中，Organogenesis Holdings Inc.、百利高、Sunshine Biopharma Inc C/Wts 涨幅较大，Organogenesis Holdings Inc.、苏轩堂、Petros Pharmaceuticals, Inc.较为活跃，换手率分别为31.48%、11.69%、8.11%，振幅较大的相关个股有Organogenesis Holdings Inc.、Sunshine Biopharma Inc C/Wts 、苏轩堂，振幅分别为57.65%、44.90%、18.00%。Pacira Biosciences, Inc.公司简介：Pacira BioSciences Inc 是一家非阿片类疼痛管理和再生健康解决方案的提供商，致力于推进和改善医疗从业者及其患者的效果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301001127a2581ab5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301001127a2581ab5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PCRX","BK4007"],"gpt_icon":0},{"id":"2514353594","title":"Pacira BioSciences(PCRX.US)：2024年Q4财报实现营收1.873亿美元，前值为1.812亿美元，预期值为1.854亿美元；每股收益为0.91美元，前值为0.89美元，预期值为0.83美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514353594","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514353594?lang=zh_cn&edition=full","pubTime":"2025-02-28 05:21","pubTimestamp":1740691300,"startTime":"0","endTime":"0","summary":"Pacira BioSciences(PCRX.US)：2024年Q4财报实现营收1.873亿美元，前值为1.812亿美元，预期值为1.854亿美元；每股收益为0.91美元，前值为0.89美元，预期值为0.83美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28052148442333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["PCRX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pacira.com","stockEarnings":[{"period":"1week","weight":0.0224},{"period":"1month","weight":-0.1923},{"period":"3month","weight":-0.0476},{"period":"6month","weight":-0.166},{"period":"1year","weight":-0.2003},{"period":"ytd","weight":-0.1886}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Pacira BioSciences, Inc.成立于2006年12月，自2007年3月以来一直在开展与EXPAREL相关的业务。该公司是一家专注于开发、商业化和制造医药产品的专业制药公司，基于公司专有的DepoFoam给药技术，主要用于医院和门诊手术中心。该公司经营一个可报告的分部。2011年10月28日，美国食品药品监督管理局（FDA）批准了公司的新药申请，即NDA，用于公司的主要候选产品EXPAREL，一种布比卡因的脂质体注射液，一种适用于浸润到手术部位以产生术后镇痛长达72小时的酰胺型局部麻醉剂。该公司认为，EXPAREL解决了对长效非阿片类术后镇痛剂的重大未满足的医疗需求，从而简化了术后疼痛管理并减少了阿片类药物的消耗，从而改善了患者的治疗效果并提高了医院经济效益。公司发展了一支完全致力于将EXPAREL商业化的内部销售队伍，公司于2012年4月将其商业化推出。此外，继试点计划后，自2013年10月1日起，公司任命CrossLink BioScience，LLC或CrossLink作为独家第三方分销商，为期五年，在美国推广和销售用于骨科和脊柱手术的EXPAREL，但某些地理区域和账户除外，可能会根据双方协议进行变更和调整。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.04958},{"month":2,"riseRate":0.666667,"avgChangeRate":0.021583},{"month":3,"riseRate":0.466667,"avgChangeRate":-0.005065},{"month":4,"riseRate":0.6,"avgChangeRate":0.040098},{"month":5,"riseRate":0.533333,"avgChangeRate":0.021597},{"month":6,"riseRate":0.4,"avgChangeRate":0.013306},{"month":7,"riseRate":0.4,"avgChangeRate":-0.031855},{"month":8,"riseRate":0.533333,"avgChangeRate":0.016779},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.011519},{"month":10,"riseRate":0.266667,"avgChangeRate":-0.02773},{"month":11,"riseRate":0.733333,"avgChangeRate":0.066003},{"month":12,"riseRate":0.6,"avgChangeRate":0.042036}],"exchange":"NASDAQ","name":"Pacira Pharmaceuticals","nameEN":"Pacira Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pacira Pharmaceuticals(PCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Pacira Pharmaceuticals(PCRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Pacira Pharmaceuticals,PCRX,Pacira Pharmaceuticals股票,Pacira Pharmaceuticals股票老虎,Pacira Pharmaceuticals股票老虎国际,Pacira Pharmaceuticals行情,Pacira Pharmaceuticals股票行情,Pacira Pharmaceuticals股价,Pacira Pharmaceuticals股市,Pacira Pharmaceuticals股票价格,Pacira Pharmaceuticals股票交易,Pacira Pharmaceuticals股票购买,Pacira Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pacira Pharmaceuticals(PCRX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Pacira Pharmaceuticals(PCRX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}